MCID: IMP005
MIFTS: 56

Impotence

Categories: Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Impotence

MalaCards integrated aliases for Impotence:

Name: Impotence 11 53 14
Erectile Dysfunction 11 28 53 41 14 16 71 75
Erectile Dysfunction Adverse Event 71
Sexual Impotence 11

Classifications:



External Ids:

Disease Ontology 11 DOID:1875
NCIt 49 C3133
UMLS 71 C0242350 C1961100

Summaries for Impotence

MedlinePlus: 41 Erectile dysfunction (ED) is a common type of male sexual dysfunction. It is when a man has trouble getting or keeping an erection. ED becomes more common as you get older. But it's not a natural part of aging. Some people have trouble speaking with their doctors about sex. But if you have ED, you should tell your doctor. ED can be a sign of health problems. It may mean your blood vessels are clogged. It may mean you have nerve damage from diabetes. If you don't see your doctor, these problems will go untreated. Your doctor can offer several new treatments for ED. For many men, the answer is as simple as taking a pill. Getting more exercise, losing weight, or stopping smoking may also help. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Impotence, also known as erectile dysfunction, is related to vasculogenic impotence and prolactinoma, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Impotence is PDE5A (Phosphodiesterase 5A), and among its related pathways/superpathways are Signal Transduction and MIF Mediated Glucocorticoid Regulation. The drugs Nebivolol and Selegiline have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, prostate and spinal cord, and related phenotypes are homeostasis/metabolism and normal

Disease Ontology: 11 A sexual dysfunction that is characterized by persistent or recurrent inability to achieve or to maintain an erection during sexual activity.

Wikipedia: 75 Erectile dysfunction (ED), also called impotence, is the type of sexual dysfunction in which the penis... more...

Related Diseases for Impotence

Diseases related to Impotence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 832)
# Related Disease Score Top Affiliating Genes
1 vasculogenic impotence 32.9 PDE5A ACE
2 prolactinoma 31.9 VIP TGFB1 SHBG PRL
3 conn's syndrome 31.9 PRL KNG1 EDN1 CYP3A4 ACE
4 lipid metabolism disorder 31.5 SHBG PDE5A NOS3 EDN1 CYP3A4 ACE
5 arteries, anomalies of 31.5 VEGFA NOS3 EDN1 ACE
6 apnea, obstructive sleep 31.5 VEGFA NOS3 EDN1 ACE
7 priapism 31.4 PDE5A NOS3 NOS2 EDN1
8 nonarteritic anterior ischemic optic neuropathy 31.3 VEGFA PDE5A NOS3 EDN1
9 hyperprolactinemia 31.2 VIP SHBG PRL
10 peyronie's disease 31.2 TGFB1 PDE5A NOS3 NOS1
11 optic nerve disease 31.2 VEGFA PDE5A EDN1 ACE
12 cardiovascular system disease 31.1 SHBG PDE5A NOS3 NOS2 KNG1 EDNRA
13 lipoprotein quantitative trait locus 31.1 VEGFA PDE5A NOS3 NOS2 KNG1 EDN1
14 type 2 diabetes mellitus 31.1 VEGFA TGFB1 SHBG PRL PDE5A NOS3
15 peripheral artery disease 30.9 VEGFA NOS3 ACE
16 microvascular complications of diabetes 5 30.9 VEGFA NOS3 NOS2 ACE
17 stroke, ischemic 30.8 VEGFA NOS3 EDNRA ANGPT1 ACE
18 hypogonadism 30.7 SHBG PRL PDE5A KLK3
19 heart disease 30.7 VEGFA TGFB1 PDE5A NOS3 NOS2 NOS1
20 bladder neck obstruction 30.7 PDE5A KLK3 ACE
21 systemic scleroderma 30.7 VEGFA EDNRA EDN1 ACE
22 peripheral vascular disease 30.6 VEGFA PDE5A NOS3 EDN1 ACE
23 vascular disease 30.6 VEGFA TGFB1 PDE5A NOS3 NOS2 KNG1
24 hypoactive sexual desire disorder 30.6 SHBG PRL PDE5A
25 varicocele 30.6 VEGFA SHBG PRL NOS3
26 arteriosclerosis 30.5 SHBG EDNRA EDN1 ACE
27 peyronie disease 30.5 TGFB1 PDE5A NOS2
28 orthostatic intolerance 30.5 NOS3 NOS2 ACE
29 congestive heart failure 30.5 VEGFA PDE5A KNG1 EDNRA EDN1 ANGPT1
30 peripheral nervous system disease 30.5 VIP VEGFA KNG1 EDN1 CYP3A4 ACE
31 microvascular complications of diabetes 1 30.5 VEGFA EDN1 ANGPT1
32 alopecia, androgenetic, 1 30.5 SRD5A1 SHBG
33 insulin-like growth factor i 30.5 VEGFA TGFB1 SHBG PRL
34 androgenic alopecia 30.5 VEGFA SRD5A1 SHBG PRL
35 systolic heart failure 30.4 PDE5A EDN1 ACE
36 nonobstructive coronary artery disease 30.4 NOS3 EDN1 ACE
37 exanthem 30.4 VEGFA CYP3A4 ACE
38 pulmonary disease, chronic obstructive 30.4 TGFB1 PDE5A PDE4A ACE
39 buerger disease 30.4 VEGFA NOS3 EDN1
40 diabetic angiopathy 30.4 VEGFA NOS3 EDN1
41 lung disease 30.3 VEGFA TGFB1 PDE4A EDN1 ACE
42 bowel dysfunction 30.3 VIP CYP3A4 ACE
43 skin disease 30.3 VIP VEGFA SRD5A1 PDE4A KNG1 CYP3A4
44 portal hypertension 30.2 NOS3 EDNRA EDN1 ACE
45 angina pectoris 30.2 NOS3 KNG1 EDN1 ACE
46 aortic aneurysm 30.2 VEGFA TGFB1 NOS3 ACE
47 sexual health disorder 30.2 SHBG PRL PDE5A
48 carotid stenosis 30.2 VEGFA NOS3 ACE
49 ischemia 30.2 VEGFA PDE5A NOS3 NOS2 NOS1 KNG1
50 prostatitis 30.2 TGFB1 PRL PDE5A KLK3

Graphical network of the top 20 diseases related to Impotence:



Diseases related to Impotence

Symptoms & Phenotypes for Impotence

UMLS symptoms related to Impotence:


tremor; angina pectoris; equilibration disorder; pelvic pain; symptom/complaint potency (excluding p07 p08); inability to maintain erection; unable to perform sex

GenomeRNAi Phenotypes related to Impotence according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.2 ACE ANGPT1 CYP3A4 EDN1 EDNRA KCNMA1
2 no effect GR00402-S-2 10.2 ACE CYP3A4 EDN1 KCNMA1 KLK3 KNG1

MGI Mouse Phenotypes related to Impotence:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.21 ACE ANGPT1 CYP3A4 EDN1 EDNRA KCNMA1
2 normal MP:0002873 10.18 CYP3A4 EDN1 EDNRA KLK3 NOS1 NOS3
3 renal/urinary system MP:0005367 10.16 ACE ANGPT1 EDN1 EDNRA KCNMA1 NOS1
4 muscle MP:0005369 10.13 ANGPT1 EDN1 EDNRA KCNMA1 KLK3 NOS1
5 endocrine/exocrine gland MP:0005379 10.06 ACE EDN1 EDNRA NOS1 NOS2 NOS3
6 liver/biliary system MP:0005370 10.01 ACE NOS1 NOS2 NOS3 PDE5A PRL
7 cardiovascular system MP:0005385 9.97 ACE ANGPT1 EDN1 EDNRA KCNMA1 KLK3
8 digestive/alimentary MP:0005381 9.86 EDN1 EDNRA KCNMA1 NOS1 NOS2 NOS3
9 immune system MP:0005387 9.77 ACE ANGPT1 EDNRA KCNMA1 NOS1 NOS2
10 reproductive system MP:0005389 9.36 ACE KCNMA1 NOS1 NOS2 NOS3 PDE3A

Drugs & Therapeutics for Impotence

Drugs for Impotence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 238)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
2
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9, 14611-52-0 5195 26757
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Nitric Oxide Approved Phase 4 10102-43-9 145068
5
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
6
Allantoin Approved Phase 4 97-59-6 204
7
Curcumin Approved, Investigational Phase 4 458-37-7, 84765-67-3 969516
8
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
9
Yohimbine Approved, Investigational, Vet_approved Phase 4 146-48-5 8969
10
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
11
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
12
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
13
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
14
Testosterone Approved, Investigational Phase 4 58-22-0 5408 6013
15
Methyltestosterone Approved Phase 4 58-18-4 6010
16
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0 21873174 65157
17
Testosterone enanthate Approved Phase 4 315-37-7 9416
18
Arginine Approved, Investigational, Nutraceutical Phase 4 74-79-3 6322
19
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
20 Protective Agents Phase 4
21 Neuroprotective Agents Phase 4
22 Antiparkinson Agents Phase 4
23 Monoamine Oxidase Inhibitors Phase 4
24 Vardenafil Dihydrochloride Phase 4
25 Antihypertensive Agents Phase 4
26 Angiotensin Receptor Antagonists Phase 4
27 Neurotransmitter Agents Phase 4
28 Adrenergic Agents Phase 4
29 Adrenergic Antagonists Phase 4
30 Adrenergic alpha-Antagonists Phase 4
31 Calcium, Dietary Phase 4
32 Anticoagulants Phase 4
33 Chelating Agents Phase 4
34 Calcineurin Inhibitors Phase 4
35 Insulin, Globin Zinc Phase 4
36
Insulin Phase 4
37 Hypoglycemic Agents Phase 4
38 Yohimbe Phase 4
39 Mydriatics Phase 4
40
Angiotensinogen Phase 4 16133225
41 Angiotensin II Type 1 Receptor Blockers Phase 4
42 Giapreza Phase 4
43 Anesthetics Phase 4
44 Anesthetics, Local Phase 4
45 Phosphodiesterase 5 Inhibitors Phase 4
46 Anabolic Agents Phase 4
47 Antineoplastic Agents, Hormonal Phase 4
48 Hormones Phase 4
49 Hormone Antagonists Phase 4
50 Androgens Phase 4

Interventional clinical trials:

(show top 50) (show all 534)
# Name Status NCT ID Phase Drugs
1 Observational Study to Evaluate the Effect of Tadalafil 5mg Once Daily on Erectile Dysfunction and QOL in Andropause Patients With Erectile Dysfunction Unknown status NCT02943356 Phase 4 Tadalafil
2 Nebivolol Effects on Endothelial Function and Erectile Function in Non-smoking Pre-hypertensive and Newly Diagnosed Stage 1 Hypertensive Men With Erectile Dysfunction. Unknown status NCT01885988 Phase 4 Nebivolol;Sugar Pill
3 Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate i.m. 1000 mg. A Prospective, Multi-Center Clinical Study Phase IV. Unknown status NCT00555087 Phase 4 Testosterone Undecanoate and/or PDE-5
4 a Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial of Efficacy and Safety of Shu Gan yi Yang Capsule in the Treatment of Depression Associated With Erectile Dysfunction (Stagnation of Liver qi and Kidney Deficiency) Unknown status NCT03290313 Phase 4 shu gan yi yang capsule;shu gan yi yang capsule simulation agent
5 Multi-Centre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury Unknown status NCT00725790 Phase 4 Vardenafil;Placebo
6 Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction: Non- Inferiority, Randomized, Crossover, Open Clinical Trial Unknown status NCT03169582 Phase 4 Avanafil;Sildenafil
7 A Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial to Evaluate the Efficacy and Safety of Udenafil Dosed Once a Day in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy Unknown status NCT03142542 Phase 4 ZYDENA TAB.75mg(Udenafil 75mg);Placebo Oral Tablet
8 Post-Prostatectomy Erectile Dysfunction: Effect of Hyperbaric Oxygen Therapy Unknown status NCT00906269 Phase 4 Sildenafil therapy plus post-NSRRP HBO2T;Sildenafil therapy plus sham post-NSRRP HBO2T
9 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
10 An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction. Unknown status NCT02225548 Phase 4 Selegiline;Tadalafil
11 The Effect of Treatment for ED on Quality of Life and Satisfaction in a Group of Patients Without Prior Complaints of Sexual Dysfunction Unknown status NCT00313898 Phase 4 sildenafil (viagra)
12 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT01364701 Phase 4 Sildenafil 100 mg;Tadalafil 20 mg;Combination half of maximal dose for sildenafil & tadalafil
13 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT00498680 Phase 4 Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil
14 Assessment of Serum YKL-40 Level and Platelets Indices Among Patients With Diabetic Erectile Dysfunction Completed NCT05446493 Phase 4 Tadalafil 5mg
15 A Randomized, Double Blind, Placebo Controlled, Flexible Dose, Multicentre Study of Levitra in a Broad Population of Men With Erectile Dysfunction and Previously Untreated With PDE5 Inhibitors. Completed NCT00668096 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
16 A Randomised, Double-blind, Double-dummy, Parallel-group, Active-controlled Study Evaluating the Efficacy of Vardenafil Versus Tadalafil When Intercourse is Attempted Within 45 Minutes of Administration in Subjects With Erectile Dysfunction Completed NCT00663130 Phase 4 Levitra (Vardenafil, BAY38-9456);Tadalafil
17 An Open-label, Multi-center, Factorial Design, Cluster-randomized Clinical Study of Vardenafil in Canadian Males With Erectile Dysfunction: Impact of Education of the Primary Care Physician and Patient on Patient Outcomes. Completed NCT00664833 Phase 4
18 An International, Multicentre, Randomized, Parallel Group, Double Blind, Placebo Controlled, Flexible Dose Study to Evaluate Self-esteem and Relationships in Males With Erectile Dysfunction Treated With Sildenafil Citrate Completed NCT00648596 Phase 4 sildenafil;placebo
19 A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Viagra® (Sildenafil Citrate) on the PRN Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes Completed NCT00645268 Phase 4 sildenafil;placebo
20 A Placebo-Controlled, Randomized, Two-Way Cross-Over, Double-Blind, Flexible Dose, Multicenter Study to Evaluate the Efficacy and Safety of Viagra in Male Patients With Traumatic Spinal Cord Injury and Erectile Dysfunction Completed NCT00654082 Phase 4 sildenafil;placebo
21 Evaluation of Systemic and Penile Microvascular Endothelial Function and Arterial Pressure After Chronic Administration of Sildenafil in Hypertensive Men With Erectile Dysfunction Completed NCT02620995 Phase 4 sildenafil citrate
22 Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction (ED) Patients Previously Treated With Other Oral ED Therapy Completed NCT00422578 Phase 4 tadalafil
23 Phase IV Study of The Therapy of Long-acting Testosterone Undecanoate,1000mg in 4 ml Oily Solution for i.m.Injection(Nebido) as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction Completed NCT00421460 Phase 4 Testosterone Undecanoate,1000mg
24 A Randomized, Double Blind, Parallel Group Study of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction and Their Female Partners Sexual Quality of Life. PARTNER II Completed NCT00377793 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
25 A Randomized, Double Blind, Placebo-controlled, Parallel Group, Multi-center Study to Investigate the Responsiveness of the Erectile Quality Scale (EQS) to Vardenafil HCl Flexible Dose Versus Placebo in Males With Erectile Dysfunction. Completed NCT00665340 Phase 4 Placebo;Levitra (Vardenafil, BAY38-9456)
26 A Rand, db, Parallel-group, Plac-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administered for 12 Weeks in a Flexible-dose Regimen Compared to Plac in Men With Diabetes Mellitus Type 1 and Erectile Dysfunction Completed NCT00660998 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
27 A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men With Erectile Dysfunction Completed NCT01698684 Phase 4 Placebo;Avanafil 100 mg;Avanafil 200 mg
28 Multi-centre, Randomized, Double-blind, Parallel, Placebo-controlled Clinical Study to Assess the Efficacy and Tolerability of Vardenafil and Its Influence on Self-esteem and Self Confidence in Subjects With Erectile Dysfunction. Completed NCT00665054 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
29 A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Viagra (Sildenafil Citrate) And Cialis (Tadalafil) Completed NCT00644956 Phase 4 tadalafil;sildenafil
30 Does Presence of Distress Due to Erectile Dysfunction Affect the Effect of Tadalafil on Sexual Life and Life Satisfaction? Completed NCT00547599 Phase 4 tadalafil
31 Open-label, Multi-centre, Study to Investigate the Safety, Tolerability and Efficacy of Flexible Doses of Vardenafil Given on Demand in Males With Erectile Dysfunction Completed NCT00681772 Phase 4 Levitra (Vardenafil, BAY38-9456)
32 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia. Completed NCT00663845 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
33 Open-Label, Multi-Centre, Study of Levitra 10 mg Once a Day in Males With Erectile Dysfunction Was Carried Out in Four Centres Namely Lagos, Port Harcourt, Enuge and Maiduguri at Their University Teaching Hospitals Completed NCT00662441 Phase 4 Levitra (Vardenafil, BAY38-9456)
34 Double-blind, Placebo Controlled, Randomized Study of Vardenafil to Determine Efficacy on Erectile Dysfunction (ED) in Men With ED and Metabolic Syndrome (ED-METABOLIC) Completed NCT00738400 Phase 4 Vardenafil (Levitra, BAY38-9456);Placebo
35 Randomised, Double Blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Study to Evaluate the Efficacy and Tolerability of Vardenafil (BAY 38-9456) in Treatment of Male Erectile Dysfunction in Asia Completed NCT00668135 Phase 4 Vardenafil (Levitra, BAY38-9456);Placebo
36 Multicenter, Double-Blind, Randomized, Placebo-controlled Study of Flexible, Titration Dose Administered on an As Needed Basis (PRN) to Evaluate the Efficacy and the Safety of Sildenafil for the Treatment of Erectile Dysfunction in Male Patients on Hemodialysis Completed NCT00654017 Phase 4 placebo;sildenafil
37 A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate) In The United States Completed NCT00644631 Phase 4 sildenafil;placebo
38 Oral Administration of L-Arginine in Patients With Erectile Dysfunction Completed NCT00777075 Phase 4 L-arginine;Placebo
39 Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Assessment of Treatment Preference Completed NCT00547352 Phase 4 tadalafil;sildenafil
40 A Multicenter Open-Label Study to Determine Treatment Preference of Tadalafil (IC351, LY450190) or Sildenafil Citrate in the Oral Treatment of Erectile Dysfunction Completed NCT00547092 Phase 4 tadalafil;sildenafil
41 Androgen Modulation of Response to Selective Phosphodiesterase Inhibitors in Erectile Dysfunction Completed NCT00512707 Phase 4 Sildenafil citrate (open label);Testosterone gel
42 A Multicenter, Open Label, High Dose (100mg) Rapid Titration Study, To Evaluate The Efficacy And Satisfaction Of Patrex® (Sildenafil Citrate) In Men With Erectile Dysfunction In Mexico. Completed NCT00468650 Phase 4 sildenafil citrate
43 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia Completed NCT00379756 Phase 4 LEVITRA (vardenafil);placebo
44 Multicenter Randomized Double-Blind, Placebo-Controlled, Fixed-Dose Parallel Study Of Men With Mild To Moderate Erectile Dysfunction To Evaluate The Efficacy Of Viagra 8 Hours Post-Dose - II Completed NCT00143260 Phase 4 Viagra (Sildenafil Citrate) 100 mg
45 A Multicenter, Randomized, Parallel Group, Double-blind, Placebo-controlled Flexible Dose Study With and Open-label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States Completed NCT00143221 Phase 4 Viagra;Placebo
46 Effectiveness Of An Educational Program To Improve Patients' Satisfaction Regarding Their Management Of Erectile Dysfunction With Sildenafil Completed NCT00159848 Phase 4
47 An Open-Label, Non-Comparative Study To Evaluate Treatment Responsiveness To The Quality Of Erection Questionnaire (QEQ) In Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate) Completed NCT00151463 Phase 4 sildenafil citrate
48 Impact of Tadalafil (LY450190) Once a Day or Tadalafil on Demand Compared to Sildenafil Citrate on Demand on Treatment Discontinuation in Patients With Erectile Dysfunction Who Are naïve to PDE5 Inhibitors Completed NCT01122264 Phase 4 Tadalafil;Sildenafil Citrate
49 A Multicenter, Parallel Group Flexible Dose Study With A Double Blind, Randomized, Placebo Controlled Phase And An Open-Label Phase To Evaluate The Quality Of Erections In Men With Erectile Dysfunction Treated With Sildenafil Citrate Completed NCT00159900 Phase 4 Sildenafil Citrate
50 A Multi-Center, Flexible Dose Study With A Double-Blind, Randomized, Placebo-Controlled Phase Followed By An Open-Label Phase To Evaluate The Impact Of Treatment With Sildenafil Citrate On The Symptoms Of Depression And Quality Of Life (Qol) Of Male Patients With Erectile Dysfunction (ED) Completed NCT00159809 Phase 4 Viagra (Sildenafil citrate)

Search NIH Clinical Center for Impotence

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ginseng Preparation
Methyltestosterone
METHYLTESTOSTERONE PWDR
Papaverine
Papaverine Hydrochloride
yohimbine
Yohimbine hydrochloride

Genetic Tests for Impotence

Genetic tests related to Impotence:

# Genetic test Affiliating Genes
1 Erectile Dysfunction 28

Anatomical Context for Impotence

Organs/tissues related to Impotence:

MalaCards : Bone Marrow, Prostate, Spinal Cord, Smooth Muscle, Kidney, Endothelial, Bone

Publications for Impotence

Articles related to Impotence:

(show top 50) (show all 22475)
# Title Authors PMID Year
1
Analyzing the Clinical Efficacy of a Type 5 Phosphodiesterase Inhibitor Combined With Ziyin Baihuo Granules in the Treatment of Erectile Dysfunction. 62 41
36444907 2022
2
Discontinuation Rates of Tadalafil Alone and in Combination with a-Blockers in the Treatment of Male Lower Urinary Tract Symptoms with or without Coexisting Erectile Dysfunction: A Systematic Review and Meta-Analysis. 62 41
36419863 2022
3
Mental and Sexual Health of Men in Times of COVID-19 Lockdown. 41
36430046 2022
4
Toxicological evaluation of a dietary supplement formulated for male sexual health prior to market release. 53 62
20043970 2010
5
Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. 53 62
20402554 2010
6
T-786C polymorphism in promoter of eNOS gene as genetic risk factor in patients with erectile dysfunction in Turkish population. 53 62
19800665 2010
7
Adaptive spaced education improves learning efficiency: a randomized controlled trial. 53 62
20022032 2010
8
Pharmacotherapy for erectile dysfunction. 53 62
20092451 2010
9
Increased cyclic guanosine monophosphate production and endothelial nitric oxide synthase level in mononuclear cells from sildenafil citrate-treated patients with erectile dysfunction. 53 62
19907424 2010
10
Ten-year follow-up of sildenafil use in spinal cord-injured patients with erectile dysfunction. 53 62
19686427 2009
11
Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. 53 62
19884625 2009
12
[Efficacy and safety of tadalafil for erectile dysfunction: an updated review]. 53 62
20112748 2009
13
Is penile length a factor in treatment of erectile dysfunction with PDE-5 inhibitor? 53 62
19234311 2009
14
Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study. 53 62
19701217 2009
15
Association of coronary artery disease, erectile dysfunction, and endothelial nitric oxide synthase polymorphisms. 53 62
19466514 2009
16
Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors. 53 62
19387454 2009
17
Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. 53 62
19377497 2009
18
Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients. 53 62
19210710 2009
19
EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor. 53 62
19036180 2009
20
In men with erectile dysfunction, satisfaction with quality of erections correlates with erection hardness, treatment satisfaction, and emotional well-being. 53 62
19143914 2009
21
[Psychosis and sexuality]. 53 62
19365914 2009
22
Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. 53 62
19138360 2009
23
Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils. 53 62
19010346 2009
24
Online spaced education to teach urology to medical students: a multi-institutional randomized trial. 53 62
18614145 2009
25
PDE5 inhibitors in non-urological conditions. 53 62
19860698 2009
26
Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study. 53 62
19125990 2009
27
Aspects of sexual satisfaction in men with erectile dysfunction: a factor analytic and logistic regression approach. 53 62
19170852 2009
28
[Tadalafil for erectile dysfunction: excellent safety and tolerance]. 53 62
19288756 2009
29
Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction. 53 62
18976905 2008
30
New treatments for localized prostate cancer. 53 62
19095127 2008
31
5-alpha reductase inhibitors and erectile dysfunction: the connection. 53 62
19090946 2008
32
The role of combination medical therapy in benign prostatic hyperplasia. 53 62
19002123 2008
33
Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction. 53 62
18528398 2008
34
Recreational use of PDE5 inhibitors by young healthy men: recognizing this issue among medical students. 53 62
18331258 2008
35
Pulmonary embolism after tadalafil ingestion. 53 62
18548330 2008
36
The effect of 5 alpha-reductase inhibitors on erectile function. 53 62
18421068 2008
37
[Tadalafil for erectile dysfunction: outstanding efficacy for 36 hours]. 53 62
18998474 2008
38
Potent inhibition of human phosphodiesterase-5 by icariin derivatives. 53 62
18778098 2008
39
Safety of prescribing PDE-5 inhibitors via e-medicine vs traditional medicine. 53 62
18674473 2008
40
Gene therapy via inducible nitric oxide synthase: a tool for the treatment of a diverse range of pathological conditions. 53 62
18644193 2008
41
Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. 53 62
18395326 2008
42
Interactive spaced education versus web based modules for teaching urology to medical students: a randomized controlled trial. 53 62
18423715 2008
43
A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. 53 62
18281145 2008
44
[Expressions of eNOS and connexin 43 in the penile tissue of rats with diabetic erectile dysfunction]. 53 62
18572862 2008
45
Efficacy and tolerability of vardenafil in Asian men with erectile dysfunction. 53 62
18385912 2008
46
[Type V phosphodiesterase inhibitor erection-provoking test with audio-visual sexual stimulation for the diagnosis of erectile dysfunction]. 53 62
18572866 2008
47
The effect of physician and patient education when combined with vardenafil treatment in Canadian males with erectile dysfunction: an open-label, factorial-designed, cluster-randomized clinical trial. 53 62
18304285 2008
48
Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms. 53 62
18075506 2008
49
Absence of hypogonadism in a male patient with a giant prolactinoma: a clinical paradox. 53 62
18082643 2008
50
Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. 53 62
18086159 2008

Variations for Impotence

Expression for Impotence

Search GEO for disease gene expression data for Impotence.

Pathways for Impotence

Pathways related to Impotence according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1 13.56 ANGPT1 EDN1 EDNRA KLK3 KNG1 NOS3
2
Show member pathways
13.51 VEGFA TGFB1 NOS3 NOS2 NOS1 EDNRA
3
Show member pathways
13.15 VEGFA TGFB1 PDE5A NOS3 NOS2 NOS1
4
Show member pathways
12.82 VEGFA PRL NOS3 NOS2 NOS1 ANGPT1
5
Show member pathways
12.14 PDE5A NOS3 NOS2 NOS1 KCNMA1
6 11.83 VEGFA TGFB1 NOS2
7
Show member pathways
11.77 NOS3 NOS2 NOS1
8
Show member pathways
11.69 TGFB1 NOS3 NOS1 KNG1 CYP3A4 ACE
9 11.57 VEGFA NOS2 EDN1
10
Show member pathways
11.52 NOS3 NOS2 NOS1
11 11.48 VEGFA TGFB1 NOS2
12 11.47 EDN1 NOS3 VEGFA
13 11.46 ANGPT1 NOS3 VEGFA
14 11.45 NOS1 PDE3A PDE4A PDE5A
15 11.35 PDE3A NOS3 NOS2 NOS1
16
Show member pathways
11.3 NOS3 NOS2 NOS1
17 11.19 VEGFA NOS2 EDN1 ANGPT1
18 11.18 NOS3 EDNRA EDN1
19 11.05 NOS3 NOS2 NOS1
20
Show member pathways
10.99 PRL NOS3 NOS2 NOS1 EDNRA EDN1
21
Show member pathways
10.93 PDE5A NOS3 NOS2 NOS1 KCNMA1
22 10.79 VEGFA NOS1
23 10.67 PDE5A NOS3 NOS2 NOS1
24 10.59 VEGFA NOS3

GO Terms for Impotence

Cellular components related to Impotence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vesicle membrane GO:0012506 9.1 NOS1 NOS2 NOS3

Biological processes related to Impotence according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 10.38 ACE EDN1 NOS2 TGFB1 VEGFA
2 in utero embryonic development GO:0001701 10.31 VEGFA NOS3 EDNRA EDN1 ANGPT1
3 response to xenobiotic stimulus GO:0009410 10.25 TGFB1 SRD5A1 PDE3A EDN1 ACE
4 response to hormone GO:0009725 10.16 NOS3 NOS2 NOS1
5 response to lipopolysaccharide GO:0032496 10.16 ACE EDN1 NOS1 NOS2 NOS3
6 cell redox homeostasis GO:0045454 10.14 NOS3 NOS2 NOS1
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 10.14 VEGFA TGFB1 NOS1 ANGPT1
8 vasodilation GO:0042311 10.13 NOS3 NOS1 KNG1
9 regulation of blood pressure GO:0008217 10.13 NOS3 EDNRA EDN1 ACE
10 blood vessel remodeling GO:0001974 10.12 NOS3 EDNRA ACE
11 branching involved in blood vessel morphogenesis GO:0001569 10.09 VEGFA EDNRA EDN1
12 negative regulation of blood pressure GO:0045776 10.08 NOS3 NOS2 NOS1
13 positive regulation of MAP kinase activity GO:0043406 10.08 VEGFA TGFB1 PDE5A EDN1
14 nitric oxide biosynthetic process GO:0006809 10.02 NOS1 NOS2 NOS3
15 axonogenesis involved in innervation GO:0060385 10 EDNRA EDN1
16 negative regulation of hydrolase activity GO:0051346 10 NOS3 NOS1
17 vasoconstriction GO:0042310 10 ACE EDN1 EDNRA
18 regulation of glucose transmembrane transport GO:0010827 9.99 EDNRA EDN1
19 noradrenergic neuron differentiation GO:0003357 9.99 EDNRA EDN1
20 cardiac neural crest cell migration involved in outflow tract morphogenesis GO:0003253 9.99 EDNRA EDN1
21 nitric oxide mediated signal transduction GO:0007263 9.99 NOS3 NOS2 NOS1
22 cellular response to luteinizing hormone stimulus GO:0071373 9.98 EDNRA EDN1
23 body fluid secretion GO:0007589 9.97 VIP EDN1
24 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.97 NOS3 EDN1
25 peptidyl-cysteine S-nitrosylation GO:0018119 9.96 NOS1 NOS2
26 sympathetic neuron axon guidance GO:0097492 9.94 EDNRA EDN1
27 neural crest cell fate commitment GO:0014034 9.94 EDNRA EDN1
28 regulation of nitric oxide mediated signal transduction GO:0010749 9.93 PDE5A VEGFA
29 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.92 ACE VEGFA
30 positive regulation of guanylate cyclase activity GO:0031284 9.91 NOS3 NOS2 NOS1
31 positive regulation of blood vessel endothelial cell migration GO:0043536 9.91 VEGFA TGFB1 NOS3 ANGPT1
32 endothelin receptor signaling pathway involved in heart process GO:0086101 9.9 EDN1 EDNRA
33 regulation of sodium ion transport GO:0002028 9.89 TGFB1 NOS3 NOS1
34 cellular response to human chorionic gonadotropin stimulus GO:0044751 9.88 EDN1 EDNRA
35 positive regulation of oocyte development GO:0060282 9.87 PDE3A PDE5A
36 meiotic cell cycle process involved in oocyte maturation GO:1903537 9.86 EDN1 EDNRA
37 response to laminar fluid shear stress GO:0034616 9.85 TGFB1 ACE
38 response to salt GO:1902074 9.84 TGFB1 EDN1
39 positive regulation of odontogenesis GO:0042482 9.8 EDN1 TGFB1
40 positive regulation of vascular permeability GO:0043117 9.8 VEGFA TGFB1 PDE3A
41 negative regulation of potassium ion transport GO:0043267 9.8 VIP NOS3 NOS1
42 mononuclear cell proliferation GO:0032943 9.65 TGFB1 ACE
43 arginine catabolic process GO:0006527 9.63 NOS3 NOS2 NOS1
44 response to hypoxia GO:0001666 9.47 VEGFA TGFB1 NOS2 NOS1 KCNMA1 EDNRA
45 cellular biosynthetic process GO:0044249 9.43 NOS1 NOS2 NOS3
46 blood vessel diameter maintenance GO:0097746 9.43 NOS3 KNG1 EDN1 ACE

Molecular functions related to Impotence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 10.06 NOS3 NOS2 NOS1 CYP3A4
2 NADP binding GO:0050661 9.88 NOS3 NOS2 NOS1
3 3',5'-cyclic-nucleotide phosphodiesterase activity GO:0004114 9.8 PDE3A PDE4A PDE5A
4 cadmium ion binding GO:0046870 9.73 NOS3 NOS1
5 FMN binding GO:0010181 9.73 NOS3 NOS2 NOS1
6 arginine binding GO:0034618 9.63 NOS3 NOS2 NOS1
7 phosphoric diester hydrolase activity GO:0008081 9.54 PDE5A PDE4A PDE3A
8 tetrahydrobiopterin binding GO:0034617 9.43 NOS3 NOS2 NOS1
9 nitric-oxide synthase activity GO:0004517 9.1 NOS3 NOS2 NOS1

Sources for Impotence

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....